Biotechs Back To “New Normal,” E&Y Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
The annual report issued by Ernst & Young shows that biotech funding and revenues are back to relatively normal levels after a few years of pullback, but 2011 could be a transitional year.